Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05901428 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

StatusRecruiting
PhasePhase 3
Started2023-06-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 35 months later Jun 2026 → Jun 2029
See other at-risk trials from Fudan University

Amendment history

2026-09-29
Primary completion pushed: 2026-06 → 2029-06
Completion pushed: 2028-06 → 2032-06
2023-06-12
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-06→confirmed 2023-06-01
Study sitesdetails revised at 1 of 1 site
2023-06-04
Original filing
Fudan University
624 trials monitored
See 9 trials at risk
Breast Cancer
5,180 trials monitored
See 256 trials at risk
This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Trial Details
NCT Number NCT05901428
Lead Sponsor Fudan University
Conditions Hormone Receptor Positive HER-2 Negative Breast Cancer
Enrollment 1,736 participants
Start Date 2023-06-01
Primary Completion 2029-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-28